Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant human CCL19/MIP‑3 beta Gly22-Ser98 Accession # Q99731
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize CCL19/MIP‑3 beta -induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR7. The Neutralization Dose (ND50) is typically 0.1-0.5 µg/mL in the presence of 50 ng/mL Recombinant Human CCL19/MIP‑3 beta.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Chemotaxis Induced by CCL19/MIP-3 beta and Neutralization by Human CCL19/MIP-3 beta Antibody. Recombinant Human CCL19/MIP-3 beta (Catalog # 361-MI) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR7 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL19/MIP-3 beta (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL19/MIP‑3 beta Monoclonal Antibody (Catalog # MAB3611). The ND50 is typically 0.1-0.5 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL19/MIP-3 beta
MIP-3 beta, also known as ELC (EBI1-Ligand Chemokine), is one of many novel beta chemokines identified through bioinformatics. MIP-3 beta cDNA encodes a 98 amino acid (aa) residue precursor protein with a predicted 21 aa residue signal peptide that is cleaved to form the 77 aa residue mature secreted protein. MIP-3 beta is distantly related to other beta chemokines (20-30% aa sequence identity) and the gene for MIP-3 beta has been mapped to chromosome 9p13 rather than chromosome 17 where the genes for many human beta chemokines are clustered. MIP-3 beta has been shown to be constitutively expressed in various lymphoid tissues (including thymus, lymph nodes, appendix and spleen). The expression of MIP-3 beta is down-regulated by the anti-inflammatory cytokine IL-10. MIP-3 beta has been shown to be a unique functional ligand for CCR7 (previously referred to as the Epstein-Barr virus-induced gene 1 (EBI1) orphan receptor), a chemokine receptor that is expressed in various lymphoid tissues and activated B and T lymphocytes. EBI1 is strongly up-regulated in B cells infected with Epstein-Barr virus and T cells infected with herpesvirus 6 or 7.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.